FTC demands AbbVie divests Crohn’s treatment in Allergan buyout

07-09-2020

Muireann Bolger

FTC demands AbbVie divests Crohn’s treatment in Allergan buyout

Piotr Swat / Shutterstock.com

The US Federal Trade Commission has approved a final order regarding charges that biopharmaceutical company AbbVie’s $63 billion acquisition of Allergan would violate US federal antitrust law.


AbbVie, Allergan, FTC, Crohn's disease, mergers & acquisitions, EPI, big pharma, inhibitor drugs, competition, divest, Zenpep, Viokasiokace, Nestlé

LSIPR